CA2659662C — Concentrated methotrexate solutions
Assigned to Medac Gesellschaft fuer Klinische Spezialpraeparate mbH · Expires 2015-01-20 · 11y expired
What this patent protects
The invention relates to concentrated methotrexate solutions containing an active substance for the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically compatible solvent, in a…
USPTO Abstract
The invention relates to concentrated methotrexate solutions containing an active substance for the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically compatible solvent, in a concentration of more than 25mg/ml. The invention also relates to a ready-made syringe, a carpule containing such a pharmaceutical solution formulation, and a pen injector comprising such a carpule and/or a ready-made syringe.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.